A six-minute walk test (6MWT) provides additional information necessary to identify nonsmall cell lung cancer (NSCLC) patients who are optimal candidates for lung resection surgery, as shown in a recent study.
Treatment with abiraterone acetate (AA) or enzalutamide (ENZ) may lead to excess short-term mortality in elderly prostate cancer with pre-existing cardiovascular diseases (CVDs), reports a recent study.
Secondary surgical cytoreduction is feasible, with acceptable postoperative morbidity, but falls short of improving overall survival in patients with platinum-sensitive, recurrent ovarian cancer, according to study.
The TAPUR study – the first clinical trial conducted by the American Society of Clinical Oncology (ASCO) – may help identify new biomarker-based therapies for patients with heavily-pretreated colorectal cancer (CRC) who have HER2-positive or BRAFV600E-mutated tumours or a high tumour mutation burden (TMB) and have no standard treatment options.
Over the decade, survival has gotten better while complications have dwindled substantially among patients who underwent allogeneic haematopoietic cell transplantation, according to a study. However, cancer relapse remains the biggest obstacle to better survival outcomes.
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Incorporating basic tumour characteristics, such as hormone receptor status and tumour origin, improves the power of the cell-loss metric to predict response to treatment, according to a new study presented at the recently concluded 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).